Phase II Study of Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Patients With Locally Advanced or Metastic Pancreatic Cancer

Trial Profile

Phase II Study of Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Patients With Locally Advanced or Metastic Pancreatic Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 11 Oct 2010 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top